Figure 1.

(A) Mean tumour weights. Low-dose ML-I (30 ng per kg body weight) daily for 19 days significantly reduced the weight of tumour nodules grown from subcutaneously injected MV3 human melanoma cells, while higher doses had no significant effect. (B) Mean number of lung metastases. Mice treated with low-dose ML-I (30 ng per kg body weight) showed significantly less spontaneous LMs from subcutaneously injected human melanoma cells than the untreated control mice. The mean number of LMs in the 30 ng kg⁻¹ treatment group was reduced by more than 50%.